PT-141 (Bremelanotide): Mechanism of Action

Introduction

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide melanocortin receptor agonist with documented activity at the MC3R and MC4R receptor subtypes. Unlike compounds acting through peripheral vascular mechanisms, bremelanotide's pharmacological activity is mediated within the central nervous system (CNS). Published research has characterized its receptor binding profile, downstream intracellular signaling, and neurological effects in both preclinical models and human clinical trials. This article summarizes the reported mechanism of action as described in the peer-reviewed literature.

Receptor Targets and Binding Profile

Bremelanotide engages melanocortin receptors, a family of five class A G protein-coupled receptors (GPCRs) that mediate the actions of endogenous ligands including adrenocorticotropin (ACTH) and the melanocyte-stimulating hormones (MSH). The five receptor subtypes differ in tissue distribution and downstream functions. MC1R is expressed predominantly in melanocytes. MC2R is the canonical ACTH receptor. MC3R and MC4R are distributed throughout the CNS, with prominent expression in hypothalamic nuclei and limbic structures [1].

Bremelanotide exhibits agonist activity at both MC3R and MC4R. Published pharmacological characterization reported that the compound's binding affinity at MC4R is substantially higher than at MC1R or MC5R, positioning MC4R as the primary pharmacological target [1]. This receptor selectivity profile is consistent with the structural design of bremelanotide as a derivative of the core tetrapeptide "message sequence" of alpha-MSH (His-Phe-Arg-Trp).

Diamond and colleagues (2003) reported systematic preclinical and early clinical characterization of PT-141 as a melanocortin agonist, documenting receptor-mediated activity across multiple biological contexts [2]. The authors noted that the compound's CNS-predominant receptor distribution distinguished its mechanism from vasodilatory compounds then in clinical use.

Reported Molecular Interactions

Melanocortin receptors MC3R and MC4R are Gs-coupled GPCRs. Upon agonist binding, receptor activation leads to coupling with the stimulatory G protein alpha subunit (Gαs), which activates adenylyl cyclase and elevates intracellular cyclic adenosine monophosphate (cAMP). Downstream cAMP-mediated signaling involves protein kinase A (PKA) activation and phosphorylation of cAMP response element binding protein (CREB), initiating transcriptional changes within neurons [1].

MC4R is expressed at high density in the paraventricular nucleus (PVN) of the hypothalamus, the arcuate nucleus, the brainstem, and several limbic structures including the amygdala and hippocampus [3]. The hypothalamic distribution of MC4R has been associated with central regulatory functions related to energy homeostasis and neuroendocrine signaling. The role of MC4R in energy homeostasis was established through targeted disruption studies in mice; Huszar and colleagues (1997) reported that MC4R knockout animals developed hyperphagia and obesity, identifying MC4R as a key node in the hypothalamic feeding circuit [3].

The specific neural circuits through which MC4R agonism mediates centrally-organized responses were explored in subsequent preclinical work. Systemic administration of PT-141 in rodent models was associated with increased immunoreactivity to c-Fos — a marker of neuronal activation — in hypothalamic regions, consistent with CNS-mediated receptor engagement [2].

Downstream Neurological Effects

The downstream neurological effects attributed to MC4R agonism by bremelanotide have been characterized at multiple levels of biological organization, from receptor-level pharmacology through neural circuit activity to clinical endpoint measures.

Browning and colleagues (2022) conducted a randomized, double-blind, placebo-controlled crossover neuroimaging study in 31 premenopausal women with hypoactive sexual desire disorder, examining the effects of MC4R agonism on brain activity during visual stimulus processing [4]. The authors reported that compared with placebo, MC4R agonism was associated with modified activity in the cerebellum, supplementary motor area, and secondary somatosensory cortex in response to erotic stimuli. Enhanced functional connectivity between the amygdala and insula was also reported. The authors described these findings as consistent with alterations in self-referential processing and sensitization to stimulus salience [4].

The neuroimaging findings build on the clinical trial evidence from the RECONNECT phase 3 program, which reported statistically significant changes from baseline across validated psychometric endpoints in 1,267 premenopausal women [5]. Together, these lines of evidence situate the compound's pharmacological activity within the CNS rather than the peripheral vasculature.

Cardiovascular Pharmacology

A secondary pharmacological effect documented in the published clinical literature is a transient, self-limiting elevation in blood pressure following bremelanotide administration. Halpern and colleagues (2017) characterized cardiovascular effects using ambulatory blood pressure monitoring and reported that the subcutaneous formulation was associated with mean increases in systolic and diastolic blood pressure of approximately 4 mmHg, with effects lasting approximately four hours following administration [6].

This cardiovascular characterization informed the clinical development program's formulation strategy. Comparative pharmacokinetic data demonstrated that the subcutaneous route produced a more predictable and attenuated blood pressure signal than the intranasal route studied in earlier phases of development [6]. The subcutaneous formulation's cardiovascular profile was considered in the design of the RECONNECT phase 3 trials and is reflected in the FDA-approved prescribing information for Vyleesi [5].

Areas of Ongoing Investigation

Several aspects of bremelanotide's mechanism at the neural circuit level represent active areas of scientific inquiry in the published literature.

The precise neural pathways by which MC4R agonism in the CNS produces the clinical effects measured in the RECONNECT trials continue to be explored. The neuroimaging data reported by Browning and colleagues (2022) represent an early step in characterizing these CNS effects, and the authors identified additional hypotheses for follow-on investigation. The complexity of the melanocortin system — including contributions of both MC3R and MC4R, the opposing actions of endogenous agonists (MSH peptides) and antagonists (agouti-related protein, AgRP), and the distribution of melanocortin projections across hypothalamic, limbic, and cortical structures — continues to motivate receptor pharmacology research [1]. KPV, a tripeptide fragment of alpha-MSH, engages overlapping melanocortin receptor pathways and is surveyed in the KPV mechanism of action article.

The relative contributions of MC3R versus MC4R agonism to bremelanotide's biological effects remain an open question in the pharmacology literature. Studies using receptor-subtype-selective pharmacological tools represent a direction for future mechanistic work. Bremelanotide's activity in additional populations and contexts also remains an area that published preclinical and early clinical data have characterized as scientifically warranting further investigation [2]. The PT-141 product page provides batch-level Certificate of Analysis documentation for research applications.

References

1. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Pharmacol Rev. 2022. PMC: PMC9599618. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/

2. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. PMID: 14963471. DOI: 10.1038/sj.ijir.3901139

3. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131-141. PMID: 9019399. DOI: 10.1016/s0092-8674(00)81865-6

4. Browning KD, Bhatt DL, Maher EM, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Sex Med. 2022;19(12):1793-1806. PMID: 36189794. PMC: PMC9525110. DOI: 10.1016/j.jsxm.2022.09.004

5. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500

6. Halpern JA, Hill R, Brannigan RE. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Ther Adv Drug Saf. 2017;8(4):125-133. PMID: 27977473. PMC: PMC5338879. DOI: 10.1177/2042098616685893